SLAMF7 CAR T Cells Sleeping Beauty Gene Transfer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, particularly for relapsed and refractory patients, are limited in efficacy and safety, with existing therapies leading to short survival times and significant side effects, necessitating the development of innovative and safer therapeutic options.
Innovation Solution
The development of SLAMF7-binding chimeric antigen receptor (CAR) T cells using Sleeping Beauty gene transfer technology, which provides stable gene integration and superior anti-myeloma efficacy compared to viral vectors, along with a defined ratio of recombinant CD4+ and CD8+ T cells to ensure safety and effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If elotuzumab antibody is used to target SLAMF7 on myeloma cells, then therapeutic effect is achieved through ADCC, but on-target off-tumor cytotoxic effect occurs on normal lymphocytes
Solution Approach 1:
The patent applies local quality by creating CAR T cells with different specificities (CD19, BCMA, GPRC5D, SLAMF7) that can be selectively deployed to target myeloma cells while sparing normal lymphocytes. Each CAR construct is designed with specific antigen recognition capabilities to achieve localized therapeutic action on tumor cells expressing the target antigen.
Solution Approach 2:
The patent uses CAR T cells as an intermediary system that bridges the gap between antibody-based therapy and cellular immunity. The CAR construct acts as an intermediary element that redirects T cell specificity toward myeloma cell surface antigens, enabling precise targeting while maintaining T cell-mediated cytotoxicity and cytokine release mechanisms.
2Productivity
If viral vectors are used for gene transfer in CAR T cell production, then gene delivery efficiency is achieved, but safety concerns arise from viral integration
Solution Approach 1:
The patent extracts the harmful viral components from the gene delivery system while retaining the essential function of genetic material delivery. By replacing viral vectors with non-viral methods (lipid nanoparticles, electroporation, nucleofection), the invention removes the safety risks associated with viral integration and replication while maintaining efficient CAR gene transfer to T cells.
3Adaptability or versatility
If conventional chemotherapy and targeted therapy are used for relapsed and refractory multiple myeloma, then treatment options are provided, but efficacy is limited and side effects are significant
Solution Approach 1:
The patent applies dynamics by creating a flexible, customizable CAR T cell therapy platform that can adapt to different patient needs and disease states. The system allows selection of different target antigens (CD19, BCMA, GPRC5D, SLAMF7) based on patient-specific myeloma cell characteristics, enabling dynamic adjustment of therapeutic strategy to optimize efficacy while minimizing side effects.
Solution Approach 2:
The patent uses composite materials by combining multiple therapeutic modalities into a unified CAR T cell platform. The CAR constructs integrate antigen recognition domains, signaling domains, and costimulatory elements to create a composite therapeutic agent that combines the specificity of antibodies with the potency of cellular immunity, overcoming the limitations of conventional single-modality therapies.
Data Source
AI summary
The present invention relates to a polypeptide encoding a SLAMF7-binding chimeric antigen receptor (CAR), a polynucleotide encoding the SLAMF7-binding CAR polypeptide, a recombinant immune cell (preferably recombinant lymphocyte, more preferably recombinant T cell) comprising the polynucleotide, a method for producing recombinant immune cells and a pharmaceutical composition comprising recombinant immune cells. The recombinant immune cells and the pharmaceutical composition of the present invention may be used in methods for treating cancer in a patient thereby providing an improved treatment regimen. The inventors of the present application demonstrated that SLAMF7 CAR T-cells prepared by Sleeping Beauty gene transfer confer superior anti-myeloma efficacy in vivo compared to SLAMF7 CAR T-cells prepared by lentiviral gene transfer. Hence, SLAMF7 CAR T-cells that are prepared by virus-free SB gene transfer possess greater anti-myeloma efficacy and therapeutic potential, which leads to significantly improved clinical activity, and significantly improved clinical outcome.